Zeid Kayali
About
In The Last Decade
Zeid Kayali
31 papers receiving 1.5k citations
Hit Papers
Peers
Comparison fields: 5 of 73
- Epidemiology 1.0k
- Hepatology 762
- Endocrinology, Diabetes and Metabolism 305
- Surgery 284
- Molecular Biology 200
Countries citing papers authored by Zeid Kayali
This map shows the geographic impact of Zeid Kayali's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zeid Kayali with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zeid Kayali more than expected).
Fields of papers citing papers by Zeid Kayali
This network shows the impact of papers produced by Zeid Kayali. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zeid Kayali. The network helps show where Zeid Kayali may publish in the future.
Co-authorship network of co-authors of Zeid Kayali
This figure shows the co-authorship network connecting the top 25 collaborators of Zeid Kayali. A scholar is included among the top collaborators of Zeid Kayali based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zeid Kayali. Zeid Kayali is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 6 | |
| 3 | Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial breakdown → | 157 |
| 4 | 87 | |
| 5 | 65 | |
| 6 | 5 | |
| 7 | 97 | |
| 8 | GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease breakdown → | 257 |
| 9 | 153 | |
| 10 | 5 | |
| 11 | Superiority of Avatrombopag (AVA) to Placebo (PBO) for the Treatment of Chronic Liver Disease (CLD)-Associated Thrombocytopenia (TCP) in Patients Undergoing Scheduled Procedures: Results of 2 Randomized, PBO-Controlled Phase 3 Studies | 2 |
| 12 | 24 | |
| 13 | 35 | |
| 14 | 1 | |
| 15 | 134 | |
| 16 | 8 | |
| 17 | 19 | |
| 18 | 24 | |
| 19 | 123 | |
| 20 | 12 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.